Dillon McKenna

Dillon McKenna

Auto-generated profile, based on publicly available information

Dillon McKenna

McMaster University 2 Centre for Discovery in Cancer Research Hamilton, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2026
Verified
Other
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
Normalized gRNA read counts for chemoradiogenetic CRISPR-Cas9 screen in GBM model BT935, related to figure 2B

5 October 2026
Verified
Other
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
A) Immunoblotting of FEN1 protein in GSCs after knockout of FEN1 or AAVS1 (control), related to figure 2C and 2D. B) Immunoblotting of FEN1 protein in GSCs after knockdown of FEN1 or GFP (control), related to figure 2E.

5 October 2026
Verified
Other
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
Sensitivity to FEN1 inhibition extends to TMZ sensitization. A, Cell viability assays of GSC and NSC lines exposed to increasing concentrations of FEN1 inhibitor over 7 days. Data are represented as mean ± SE; n = 4 experimental replicates. B, Cell viability assays of NSC, FEN1i-resistant, and FEN1i-sensitive GSC lines exposed to DMSO (control), 25 μmol/L TMZ, 30 μmol/L FEN1i, or combination (TMZ and FEN1i). Dashed lines represent expected viability under combination treatment. Data are represented as mean ± SE; n = 4 experimental replicates. C and D, Synergy assays between TMZ and FEN1 inhibitor in (C) FEN1i-resistant and (D) FEN1i-sensitive GBM models. Colors correspond to Bliss excess synergy scores, wherein more positive values indicate stronger synergy; n = 4 experimental replicates. ns, not statistically significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

6 January 2026
Verified
Other
Open access
DBDavid Bakhshinyan
David Bakhshinyan
SCStefan Custers
Stefan Custers
LELaura Escudero
Laura Escudero
YSYujin Suk
Yujin Suk
KBKevin R. Brown
Kevin R. Brown
Sheila SinghSheila Singh
Sheila Singh
Supplemental Figure 6: Immunohistochemical profiling of changes in phospho-AKT1 levels in response to treatment.

6 January 2026
Verified
Other
Open access
DBDavid Bakhshinyan
David Bakhshinyan
SCStefan Custers
Stefan Custers
LELaura Escudero
Laura Escudero
YSYujin Suk
Yujin Suk
KBKevin R. Brown
Kevin R. Brown
Sheila SinghSheila Singh
Sheila Singh
Purpose:Medulloblastoma is a common pediatric brain tumor with distinct molecular subgroups. Among them, group 3 medulloblastoma is associated with increased recurrence, metastatic potential, and poor patient outcomes. Small-molecule inhibitors targeting B cell–specific Moloney murine leukemia virus insertion site 1 (BMI1) have demonstrated efficacy against several types of malignant tumors, including pediatric medulloblastoma. Although our previously published in vivo study provided a promising proof of concept for the therapeutic targeting of BMI1 in group 3 medulloblastoma with small-molecule inhibitors, it is not sufficient to eradicate the tumor.Experimental Design:In this study, following preclinical validation of BMI1 inhibitor PTC596, DNA barcoding technology was leveraged to profile in vivo clonal dynamics of group 3 medulloblastoma in response to the established chemoradiotherapy regimen alone and in combination with PTC596. Following demonstration of a small number of treatment-refractory clones, we sought to identify potential druggable molecular vulnerabilities by utilizing phosphoproteomic profiling and genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screening.Results:By comparing the changes in the phosphorylation pattern of key signaling kinases after PTC596 treatment with the list of sensitizer genes from in vitro genome-wide CRISPR/CRISPR-associated protein 9 screen and with the essential genes in human neural stem cells, we identified several context-specific regulators of mTOR, AKT, and PLK1 pathways. Subsequently, targeting the PI3K pathway with enzastaurin was most amenable to synergistic targeting alongside BMI1 inhibition.Conclusions:This work provides the foundation for clinical validation of small-molecule inhibitors synergistic with PTC596 to improve the durability of remissions and extend the survival of patients with treatment-refractory group 3 medulloblastoma.

1 October 2026 in Cancer Research Communications
Verified
Journal Article
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
Glioblastoma (GBM) is an aggressive brain tumor characterized by therapy resistance and recurrence. GBM stem cells (GSC) are key drivers of tumor maintenance, therapeutic resistance, and relapse, but targeting them remains clinically elusive due to their overlap with normal neural stem cells (NSC) and a lack of actionable vulnerabilities. To identify selective vulnerabilities in GSCs, we performed genome-wide CRISPR-Cas9 loss-of-function screening across patient-derived GSC models under standard-of-care treatment conditions. We identified flap endonuclease 1 (FEN1), a key enzyme in DNA replication and base excision repair, as an essential gene for GSC survival, with enhanced dependency in the context of temozolomide (TMZ) treatment. Genetic knockdown of FEN1 impaired GSC proliferation and self-renewal and extended survival in a patient-derived xenograft model. Pharmacologic inhibition of FEN1 using a small-molecule inhibitor revealed selective cytotoxicity in highly aggressive and recurrent GBM models while sparing NSCs. Notably, FEN1 inhibition synergized with TMZ to induce DNA double-strand breaks and potentiate cell death only in a subset of GSCs sensitive to FEN1 inhibition. Mechanistically, single-cell transcriptomics revealed that FEN1 expression correlates with programs linked to proliferation, stemness, and DNA damage repair, underscoring its role in maintaining the treatment-refractory phenotype. Our findings identify FEN1 as a selective vulnerability in aggressive, proliferative GSCs. FEN1 inhibition not only impairs GSC viability but also restores sensitivity to TMZ in treatment-resistant models, offering a strategy for salvage therapy in recurrent GBM. These results support the development of FEN1-targeted therapies and lay the foundation for a biomarker-guided approach to overcoming chemoresistance in GBM. Significance: GBM is a lethal brain tumor driven by therapy-resistant GSCs. We identified FEN1 as a selective vulnerability of GSCs that promotes TMZ resistance. FEN1 inhibition disrupts GSC self-renewal, restores TMZ sensitivity, and spares healthy NSCs, establishing FEN1 as a precision neuro-oncology target.